Upregulation of SOX11 Enhances Tamoxifen Resistance and Promotes Epithelial-to-mesenchymal Transition Via Slug in MCF-7 Breast Cancer Cells

Overview

Journal J Cell Physiol

Specialties Cell Biology
Physiology

Date 2020 Feb 12

PMID 32043610

Citations 13

Authors

Yingsheng Xiao

Qin Xie

Qingsong Qin

Yuanke Liang

Haoyu Lin

De Zeng

Affiliations

Soon will be listed here.

Abstract

Resistance to tamoxifen remains a prominent conundrum in the therapy of hormone-sensitive breast cancer. Also, the molecular underpinnings leading to tamoxifen resistance remain unclear. In the present study, we utilized the Gene Expression Omnibus database to identify that SOX11 might exert a pivotal function in conferring tamoxifen resistance of breast cancer. SOX11 was found to be markedly upregulated at both the messenger RNA and protein levels in established MCF-7-Tam-R cells compared to the parental counterparts. Moreover, SOX11 was able to activate the transcription of slug via binding to its promoter, resulting in promoting the progress of epithelial-to-mesenchymal transition and suppressing the expression of ESR1. Downregulating SOX11 expression can restore the sensitivity to 4-hydroxytamoxifen in MCF-7-Tam-R cells. Survival analysis from large sample datasets indicated that SOX11 was closely related to poorer survival in patients with breast cancer. These findings suggest a novel feature of SOX11 in contributing to tamoxifen resistance. Hence, targeting SOX11 could be a potential therapeutic strategy to tackle tamoxifen resistance in breast cancer.

Citing Articles

SOX11 and Epithelial-Mesenchymal Transition in Metastatic Serous Ovarian Cancer.

Psilopatis I, Schaefer J, Arsenakis D, Bolovis D, Levidou G Biomedicines. 2023; 11(9).

PMID: 37760985 PMC: 10526401. DOI: 10.3390/biomedicines11092540.

Systematic Investigation of the Multifaceted Role of in Cancer.

Sun Q, Du J, Dong J, Pan S, Jin H, Han X Cancers (Basel). 2022; 14(24).

PMID: 36551589 PMC: 9776339. DOI: 10.3390/cancers14246103.

SHH and Notch regulate SOX9+ progenitors to govern arcuate POMC neurogenesis.

Place E, Manning E, Kim D, Kinjo A, Nakamura G, Ohyama K Front Neurosci. 2022; 16:855288.

PMID: 36033614 PMC: 9404380. DOI: 10.3389/fnins.2022.855288.

The E3 Ligase TRIM4 Facilitates SET Ubiquitin-Mediated Degradation to Enhance ER-α Action in Breast Cancer.

Han D, Wang L, Long L, Su P, Luo D, Zhang H Adv Sci (Weinh). 2022; 9(25):e2201701.

PMID: 35843886 PMC: 9443474. DOI: 10.1002/advs.202201701.

LINC01296 promotes neuroblastoma tumorigenesis via the NCL-SOX11 regulatory complex.

Wang J, Wang Z, Lin W, Han Q, Yan H, Yao W Mol Ther Oncolytics. 2022; 24:834-848.

PMID: 35317520 PMC: 8917274. DOI: 10.1016/j.omto.2022.02.007.

References

Jager N, Linn S, Schellens J, Beijnen J . Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. Clin Breast Cancer. 2015; 15(4):241-4. DOI: 10.1016/j.clbc.2015.04.005. View

Mansouri S, Farahmand L, Hosseinzade A, Eslami-S Z, Majidzadeh-A K . Estrogen can restore Tamoxifen sensitivity in breast cancer cells amidst the complex network of resistance. Biomed Pharmacother. 2017; 93:1320-1325. DOI: 10.1016/j.biopha.2017.07.057. View

Szostakowska M, Trebinska-Stryjewska A, Grzybowska E, Fabisiewicz A . Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals. Breast Cancer Res Treat. 2018; 173(3):489-497. PMC: 6394602. DOI: 10.1007/s10549-018-5023-4. View

Araki K, Miyoshi Y . Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer. Breast Cancer. 2017; 25(4):392-401. DOI: 10.1007/s12282-017-0812-x. View

Zhang W, Wu M, Chong Q, Zhang M, Zhang X, Hu L . Loss of Estrogen-Regulated at 3p21.1 Promotes Tamoxifen Resistance in Breast Cancer. Cancer Res. 2018; 78(17):4915-4928. DOI: 10.1158/0008-5472.CAN-18-0069. View

Li Y, Wu Y, Abbatiello T, Wu W, Kim J, Sarkissyan M . Slug contributes to cancer progression by direct regulation of ERα signaling pathway. Int J Oncol. 2015; 46(4):1461-72. PMC: 4356499. DOI: 10.3892/ijo.2015.2878. View

Yuan J, Liu M, Yang L, Tu G, Zhu Q, Chen M . Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin.... Breast Cancer Res. 2015; 17:69. PMC: 4453053. DOI: 10.1186/s13058-015-0579-y. View

Shao S, Zhao X, Zhang X, Luo M, Zuo X, Huang S . Notch1 signaling regulates the epithelial-mesenchymal transition and invasion of breast cancer in a Slug-dependent manner. Mol Cancer. 2015; 14:28. PMC: 4322803. DOI: 10.1186/s12943-015-0295-3. View

Hoser M, Potzner M, Koch J, Bosl M, Wegner M, Sock E . Sox12 deletion in the mouse reveals nonreciprocal redundancy with the related Sox4 and Sox11 transcription factors. Mol Cell Biol. 2008; 28(15):4675-87. PMC: 2493363. DOI: 10.1128/MCB.00338-08. View

10.

Kim S, Lee J, Oh S, Nam S, Lee J . Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells. Oncol Rep. 2015; 34(3):1613-9. DOI: 10.3892/or.2015.4116. View

11.

Pugongchai A, Bychkov A, Sampatanukul P . Promoter hypermethylation of SOX11 correlates with adverse clinicopathological features of human prostate cancer. Int J Exp Pathol. 2018; 98(6):341-346. PMC: 5826943. DOI: 10.1111/iep.12257. View

12.

Provenzano E, Ulaner G, Chin S . Molecular Classification of Breast Cancer. PET Clin. 2018; 13(3):325-338. DOI: 10.1016/j.cpet.2018.02.004. View

13.

Mills J, Rutkovsky A, Giordano A . Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol. 2018; 41:59-65. PMC: 6454890. DOI: 10.1016/j.coph.2018.04.009. View

14.

Geng C, Li J, Ding F, Wu G, Yang Q, Sun Y . Curcumin suppresses 4-hydroxytamoxifen resistance in breast cancer cells by targeting SLUG/Hexokinase 2 pathway. Biochem Biophys Res Commun. 2016; 473(1):147-153. DOI: 10.1016/j.bbrc.2016.03.067. View

15.

Adhikary A, Chakraborty S, Mazumdar M, Ghosh S, Mukherjee S, Manna A . Inhibition of epithelial to mesenchymal transition by E-cadherin up-regulation via repression of slug transcription and inhibition of E-cadherin degradation: dual role of scaffold/matrix attachment region-binding protein 1 (SMAR1) in breast cancer.... J Biol Chem. 2014; 289(37):25431-44. PMC: 4162148. DOI: 10.1074/jbc.M113.527267. View

16.

Bertucci F, Finetti P, Guille A, Adelaide J, Garnier S, Carbuccia N . Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget. 2016; 7(19):27208-19. PMC: 5053643. DOI: 10.18632/oncotarget.8349. View

17.

Xiao Y, Xie Q, Qin Q, Liang Y, Lin H, Zeng D . Upregulation of SOX11 enhances tamoxifen resistance and promotes epithelial-to-mesenchymal transition via slug in MCF-7 breast cancer cells. J Cell Physiol. 2020; 235(10):7295-7308. PMC: 7496966. DOI: 10.1002/jcp.29629. View

18.

Layman R . CDK4/6 Inhibitors for Advanced Hormone Receptor-Positive Breast Cancer, 2019 and Beyond. J Natl Compr Canc Netw. 2019; 17(2):190-192. DOI: 10.6004/jnccn.2018.7271. View

19.

Lanara Z, Giannopoulou E, Fullen M, Kostantinopoulos E, Nebel J, Kalofonos H . Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection. Hum Genomics. 2013; 7:14. PMC: 3686617. DOI: 10.1186/1479-7364-7-14. View

20.

Zvelebil M, Oliemuller E, Gao Q, Wansbury O, Mackay A, Kendrick H . Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers. Breast Cancer Res. 2013; 15(2):R25. PMC: 3672751. DOI: 10.1186/bcr3403. View